← Leaderboards
Gloria Yf Ho
Yeshiva University
$9,326,373
Attributed
$9,530,559
Total exposure
8
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2005–17$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
Funding mix
By agency
NIH$9,530,559 · 8
By mechanism
R01$8,834,270 · 5
R21$408,372 · 1
P30$287,917 · 1
M01$0 · 1
Top collaborators
- Tao Wang2 shared
Others in their field
Top investigators on “Cancer Risk”
- Gregory H Reaman · National Childhood Cancer Foundation$242,495,090
- David Heimbrook · Leidos Biomedical Research, Inc.$222,048,828
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Philip J Disaia · University Of California Irvine$144,085,463
- Mitchell D Schnall · University Of Pennsylvania$138,156,012
- Peter C Adamson · National Childhood Cancer Foundation$128,266,602
Research focus
Cancer RiskFemaleClinical ResearchEtiologyPostmenopauseInsulinSmokingHuman SubjectGeneticBiomarkerPublic Health RelevanceSerumReceptor SignalingGenesReceptorSerologicalS HealthInsulin-Like Growth Factor ICytokineProteinsInhibitor/AntagonistPathway InteractionsInterleukin-6Physiological
Grant awards (23)
Develop and Apply a Novel Genome-wide Mendelian Randomization Method to Examine Relationship between Obesity and Lung Cancer$208,405
R21 · FY2017 · CA
Develop and Apply a Novel Genome-wide Mendelian Randomization Method to Examine Relationship between Obesity and Lung Cancer$199,967
R21 · FY2016 · CA
Serum Levels of EGFR-Signaling-Network Activators/Inhibitor and Lung Cancer Risk$560,055
R01 · FY2012 · CA · contact PI
Serum Levels of EGFR-Signaling-Network Activators/Inhibitor and Lung Cancer Risk$601,771
R01 · FY2011 · CA · contact PI
Serum Levels of EGFR-Signaling-Network Activators/Inhibitor and Lung Cancer Risk$702,820
R01 · FY2010 · CA · contact PI
Pro & Anti-Inflammatory Cytokines in Colorectal Cancer$592,165
R01 · FY2010 · CA · contact PI
Pro & Anti-Inflammatory Cytokines in Colorectal Cancer$625,384
R01 · FY2009 · CA · contact PI
Pro & Anti-Inflammatory Cytokines in Colorectal Cancer$629,761
R01 · FY2008 · CA · contact PI
Polymorphisms of INS/IGF Signal Pathways & Female Cancer$518,812
R01 · FY2006 · CA · contact PI
Aspirin, Inflammation Markers, and Colorectal Adenoma$94,336
R01 · FY2006 · CA · contact PI
Polymorphisms of INS/IGF Signal Pathways &Female Cancer$529,945
R01 · FY2005 · CA
Aspirin, Inflammation Markers, and Colorectal Adenoma$276,709
R01 · FY2005 · CA
Polymorphisms of INS/IGF Signal Pathways &Female Cancer$522,624
R01 · FY2004 · CA
Aspirin, Inflammation Markers, and Colorectal Adenoma$254,790
R01 · FY2004 · CA
SPONTANEOUS REGRESSION BIOMARKERS IN CERVIX DYSPLASIA$614,514
R01 · FY2003 · CA
Polymorphisms of INS/IGF Signal Pathways &Female Cancer$550,297
R01 · FY2003 · CA
SPONTANEOUS REGRESSION BIOMARKERS IN CERVIX DYSPLASIA$597,003
R01 · FY2002 · CA
SPONTANEOUS REGRESSION BIOMARKERS IN CERVIX DYSPLASIA$586,192
R01 · FY2001 · CA
GENETIC /NUTRITIONAL FACTORS INFLUENCING EXTENT &PROGRESSION OF PROSTATE CANCER$0
M01 · FY2001 · RR
CORE--BIOSTATISTICS FACILITY$0
P30 · FY2001 · CA
SPONTANEOUS REGRESSION BIOMARKERS IN CERVIX DYSPLASIA$577,092
R01 · FY2000 · CA
CORE--BIOSTATISTICS FACILITY$287,917
P30 · FY2000 · CA
GENETIC /NUTRITIONAL FACTORS INFLUENCING EXTENT &PROGRESSION OF PROSTATE CANCER$0
M01 · FY2000 · RR